{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Jianlin Lou"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0001808000"],"submitter_email":["jianlin@163.com"],"submitter_affiliation":["Zhejiang Academy of Medical Sciences"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"pubmed_abstract":["Malignant mesothelioma (MM) is an aggressive cancer linked to asbestos exposure. Its poor prognosis makes early diagnosis extremely important, which would provide an opportunity for early treatment and potentially changing outcomes. This study aimed to explore the underlying mechanisms of MM and discover novel noninvasive biomarkers for the diagnosis of malignant mesothelioma. Using Isobaric tags for relative and absolute quantitation (iTRAQ) combined with two-dimensional liquid chromatography/tandem mass spectrometry (2D LC-MS/MS), a total of 145 differentially expressed serum proteins were identified between MM patients and healthy controls. The identified proteins were further analyzed by bioinformatics, out of which three candidate biomarkers (Filamin A (FLNA), Fibulin 1 (FBLN1) and Thrombospondin-1 (TSP-1)) were validated in large cohorts of patients with asbestos-related diseases including MM patients by ELISA assay. Receiver operating characteristic (ROC) curve analysis showed that serum FLNA, FBLN1 and TSP-1 had high diagnostic values in distinguishing MM patients from healthy controls, individuals with asbestos exposure (AE), and patients with pleural plaques (PP) or asbestosis. Meanwhile, serum FBLN1 and TSP-1 possessed good diagnostic values in distinguishing asbestosis patients from healthy controls and individuals with AE. The combination of FLNA, FBLN1, and TSP-1 proteins had higher sensitivity and specificity in discriminating patients with MM, PP and asbestosis. Our findings indicated that analysis of serum proteome using iTRAQ is a feasible strategy for biomarker discovery, and serum FLNA, FBLN1 and TSP-1 may be promising candidates for diagnosis of malignant mesothelioma and screening of at-risk individuals."],"pubmed_title":["Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS."],"pubmed_authors":["Xia Hailing H, Feng Lingfang L, Lin Lijun L, Jiang Zhaoqiang Z, Chen Junqiang J, Shi Wei W, Ying Shibo S, Yu Min M, Ju Li L, Zhu Lijin L, Shi Li L, Zhang Xing X, Lou Jianlin J"],"additional_accession":[]},"is_claimable":false,"name":"Identification of novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS","description":"In this project, differential serum proteins (DEPs) were first screened in MM patients and healthy controls using iTRAQ labeling coupled with 2D LC-MS/MS method. As a result, 475 proteins were identified, of which, 327 proteins contain at least two unique peptides, and 145  DEPs were found between MM patients and healthy controls. Besides, all the identified proteins were subjected to bioinformatic analysis by using the Gene Ontology(GO) database，the Kyoto Encyclopedia of Genes Genomes（KEGG）database and the Cluster of Orthologous Groups of proteins(COG) database to find the relative processes that these proteins were involved in. Furthermore, function enrichment analysis (GO enrichment and KEGG enrichment) of these DEPs showed enrichment in several biological pathways which can characterize the most significant functional roles and related pathways. Candidate protein biomarkers were selected for subsequent validation in large cohorts of patients with asbestos related diseases by ELISA assay. Our findings indicated that Serum FLNA, FBLN1 and TSP-1 might be promising candidates for diagnosis of MM and screening of at-risk individuals.","dates":{"publication":"Wed Oct 30 00:00:00 GMT 2019"},"accession":"PXD016073","cross_references":{"TAXONOMY":["9606"],"pubmed":["33197421"]}}